Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

60.0%

3 terminated out of 5 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
P 2 (1)
P 4 (1)

Trial Status

Terminated3
Unknown1
Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT06984822Not ApplicableRecruiting

Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant

NCT04296838Phase 2Terminated

Effects of Conbercept in Refractory Uveitic Macular Edema and VEGF

NCT03188471Phase 4Unknown

Preventive Application of GnRH Antagonist on Early OHSS

NCT00709657Not ApplicableTerminated

The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion

NCT00735943TerminatedPrimary

Macugen Observational Study

Showing all 5 trials

Research Network

Activity Timeline